EPALRESTAT

Epalrestat inhibits aldose reductase, helping reduce diabetic neuropathy symptoms. Side effects include nausea, rash, and liver enzyme elevation.

SKU: 572f4b10a6ae Category: Tag:

Product Description


Mechanism of Action

Epalrestat is a selective aldose reductase inhibitor that blocks conversion of glucose to sorbitol in the polyol pathway. This reduces intracellular osmotic stress, oxidative damage and protein glycation—mechanisms central to diabetic neuropathy progression.

Benefits and Advantages

Used in polyol‑pathway studies, diabetic‑neuropathy modelling, oxidative‑stress research, and aldose‑reductase inhibition assays.

Side Effects and Risks

Risks include elevated liver enzymes, nausea, rash and hypersensitivity reactions. Handle with enzyme‑inhibitor precautions.

Datasheet


Molecular Formula

C15H13NO3S

Molecular Weight

319.4 g/mol

CAS Number

82159-09-9

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

>47.9 [ug/mL] (The mean of the results at pH 7.4)

Purity

Purity information is available upon request (COA).

Synonym

epalrestat; 82159-09-9; Kinedak; Epalrestatum; Ono-2235

IUPAC/Chemical Name

2-[(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]acetic acid

InChl Key

CHNUOJQWGUIOLD-NFZZJPOKSA-N

InChl Code

InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8-

References

https://pubchem.ncbi.nlm.nih.gov/compound/1549120;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download